Home ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria®

ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria®

Find out more …

FAQs
News
Contact

The final results of the pivotal PRISMA-3 study show the efficacy of both dosage strengths of the monthly injectable antipsychotic for the treatment of patients with acute exacerbation of schizophrenia.

Fri, 05/07/2019 - 12:15

Descargar noticia

Download PDF
 

Comments

Add new comment

More information about text formats

Comment User

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Related News
13/01/2021
ROVI completes the manufacture of the first batches of Moderna vaccine
27/11/2020
The Journal npj Schizophrenia Publishes the Results of the PRISMA-3 Study of the Efficacy and Safety of Doria® in Schizophrenic Patients
24/11/2020
2020 Capital Markets Day presentation